Laserfiche WebLink
opioid epidemic, including but not limited to those efforts described in Section <br />C(4)(a) through 0) of this MOU. In addition, "Approved Abatement Purposes" <br />shall include the types of efforts approved for funding by the Authority that is <br />defined in Section C(l ). "Approved Abatement Purposes" also shall include any <br />other abatement or remediation purposes to the extent such purposes are described <br />in a Settlement. <br />10. "Pharmaceutical Supply Chain" shall mean the process and channels through which <br />opioids or opioid products are manufacturcd. marketed, promoted, distributed or <br />dispensed. <br />11. "Pharmaceutical Supply Chain Participant" shall mean any entity that engages in or <br />has engaged in the manufacture, marketing, promotion, distribution, or dispensing <br />of an opioid analgesic. <br />B. Allocation of Settlement Proceeds <br />1. All Opioid Funds shall be initially divided with fifteen percent (15 %) going to the <br />Participating Political Subdivisions ( "Subdivision Share "), seventy percent (70 %) <br />going to the Virginia Opioid Abatement Fund and to other Approved Abatement <br />Purposes as further described herein ( "Opioid Abatement Share "), and fifteen <br />percent (15 %) going to the Commonwealth of Virginia ( "Commonwealth Share "). <br />2. The Subdivision Share shall be allocated and paid to the Participating Political <br />Subdivisions in accordance with the division of proceeds referenced in the schedule <br />attached hereto as Exhibit A. The shares of Virginia counties and independent cities <br />who elect not to become Participating Political Subdivisions, if any, shall be <br />reallocated ratably to the Participating Political Subdivisions. <br />3 <br />